LONDON, March 6, 2017 /PRNewswire/ -- Global Diabetic Therapeutic
The global diabetic therapeutic market is growing at a high pace owing to the increase in the prevalence of diabetes globally. The top countries with high prevalence of diabetes are China, India, the US, Brazil, Russia, Mexico, Indonesia, Egypt, Japan, and Bangladesh. It is estimated that more than 1.5 million deaths occur due to diabetes worldwide each year.
Technavio's analysts forecast the global diabetic therapeutic market to grow at a CAGR of 7.55% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global diabetic therapeutic market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded drugs, generics, and biosimilars used for the treatment of diabetes. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period..
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
Technavio's report, Global Diabetic Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- AstraZeneca
- Eli Lilly
- Merck
- Novo Nordisk
- Sanofi
Download the full report: https://www.reportbuyer.com/product/4706455/
Other prominent vendors
- AbbVie
- Actelion Pharmaceuticals
- Adocia
- Aegerion Pharmaceuticals
- Akros Pharma
- Alnylam Pharmaceuticals
- Amarin
- Amgen
- Amicus Therapeutics
- Arbutus Biopharma
- Arena Pharmaceuticals
- Astellas Pharma
- Atheronova
- Aurobindo Pharma
- Baxalta
- Belrose Pharma
- BHV Pharma
- Biocon
- Biodel
- BioMarin
- Bionaturis
- Biosidus
- Biospherics
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Catabasis Pharmaceuticals
- Cerenis Therapeutics
- Chipscreen Biosciences
- Cipla
- CJ HealthCare
- CKD Bio
- Concord Biotech
- ConjuChem
- CureDM
- CymaBay Therapeutics
- Daewoong
- Daiichi Sankyo
- Dance Biopharm
- DiaMedica
- Diamyd Therapeutics
- Diasome Pharmaceuticals
- DiaVacs
- Dong-A ST
- Eisai
- Elcelyx Therapeutics
- Esperion Therapeutics
- Exsulin
- F. Hoffmann-La Roche
- Gan & Lee Pharmaceuticals
- Generex Biotechnology
- Genfit
- GlaxoSmithKline
- HanAll BioPharma
- Hanmi Pharmaceutical
- Hua Medicine
- Iltoo Pharma
- Intarcia Therapeutics
- InteKrin Therapeutics
- Intrexon
- Ionis Pharmaceuticals
- Islet Sciences
- ISU Abxis
- Janssen Pharmaceuticals
- Japan Tobacco
- JCR Pharmaceuticals
- JW Pharmaceuticals
- Kadmon Pharmaceuticals
- Kamada
- KinDex Pharmaceuticals
- Kissei
- Kotobuki
- Kowa Company
- Laboratoires SMB
- Lexicon Pharmaceuticals
- Ligand Pharmaceuticals
- Living Cell Technologies
- Livzon
- LIXTE Biotechnology
- Lupin
- MacroGenics
- Madrigal Pharmaceuticals
- MannKind Corporation
- MedImmune
- Melior Pharmaceuticals
- Merrion Pharmaceuticals
- Merz Pharmaceuticals
- Metabolic Solutions Development
- Mitsubishi Tanabe Pharma
- Mylan
- Neothetics
- Neuraltus Pharmaceuticals
- NGM Biopharmaceuticals
- Norgine
- Novartis
- NuSirt Biopharma
- Oramed
- Orexigen Therapeutics
- Osiris Therapeutics
- Peptron
- Perle Biosciences
- Pfizer
- PhaseBio Pharmaceuticals
- Poxel
- Protalix BioTherapeutics
- Raptor
- Recordati
- Regeneron Pharmaceuticals
- REGENX BioSciences
- REGiMMUNE
- Rhythm Pharmaceuticals
- Saniona
- Santaris Pharma
- Sanwa Kagaku Kenkyusho
- Serometrix
- Shionogi
- Shire
- Sigma-Tau
- Sirona Biochem
- Strongbridge Biopharma
- Sun Pharma
- Takeda Pharmaceuticals
- Teva
- Thera Technologies
- Theracos
- Toleranzia
- Tolerion
- Torrent Pharmaceuticals
- Transition Therapeutics
- UCB
- Utrecht Holdings
- VeroScience
- Vivus
- vTv Therapeutics
- XBiotech
- Xeris Pharmaceuticals
- XOMA
- Zafgen
- Zydus Cadila
Market driver
- Change in patient preference
- For a full, detailed list, view our report
Market challenge
- Complex storage conditions and distribution policies for insulin
- For a full, detailed list, view our report
Market trend
- Focus on oral insulin therapies
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.
Methodology
Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by Government agencies.
Download the full report: https://www.reportbuyer.com/product/4706455/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article